Ovarian Cancer

A statistically significant OS benefit was observed with relacorilant plus nab-paclitaxel for patients with platinum-resistant ovarian cancer.

Delaying cytoreductive surgery until after 6 cycles of neoadjuvant chemotherapy did not improve DFS vs interval surgery after 3 cycles in patients with advanced high-grade epithelial ovarian cancer.

Across both pretreated cervical cancer and PROC populations, no new safety signals and low rates of treatment discontinuation were observed with DB-1311/BNT324.

In the phase 3 NRG-GY019 trial, while letrozole monotherapy was more tolerable, it did not achieve noninferiority compared with chemotherapy and letrozole.

Updated results from the phase 2 RAMP 201 trial show that avutometinib plus defactinib provides durable efficacy and a manageable safety profile in patients with LGSOC.

Final overall survival data from the phase 3 ROSELLA trial showed that the addition of relacorilant to nab-paclitaxel extended median survival to 16.0 months in patients with platinum-resistant ovarian cancer.

The FDA has removed the partial clinical hold on the phase 2 LINNET study of lorigerlimab for patients with platinum-resistant ovarian cancer and clear cell gynecologic cancer.

The FDA granted fast track designation to SIM0505, a CDH6-directed antibody-drug conjugate, for the management of platinum-resistant ovarian cancer.

Robert Coleman, MD, FACOG, FACS, discusses the significance of the relacorilant and nab-paclitaxel approval in PROC supported by phase 3 ROSELLA trial data.

The FDA granted FTD to CTIM-76, a CLDN6/CD3 bispecific antibody, for the treatment of patients with CLDN6-positive platinum-resistant ovarian cancer.

ZW191 is currently under evaluation in a phase 1 trial that has already demonstrated activity among patients with platinum-resistant ovarian cancer.

Updated data demonstrated a 14.7-month OS benefit when adding IMNN-001 to neoadjuvant chemotherapy in patients with newly diagnosed ovarian cancer.

Data from the ROSELLA trial support the approval of relacorilant plus nab-paclitaxel in this ovarian cancer population.

The MyChoice CDx was approved based on its performance determining HRD status and stratifying patients in the phase 3 PRIMA trial.

Updated results from the phase 3 KEYNOTE-B96 trial revealed that pembrolizumab plus paclitaxel with or without bevacizumab improved OS in all comers.

Relacorilant plus nab-paclitaxel improved PFS among patients with PROC who had progression after a PARP inhibitor or who were 65 years or older.

A partial clinical hold has been placed on the phase 2 LINNET trial following the report of several serious safety events, including 1 treatment-related death.

Treatment with relacorilant plus nab-paclitaxel yielded a 35% reduction in the risk of death compared with nab-paclitaxel alone for patients with platinum-resistant ovarian cancer.

Maveropepimut-S with pembrolizumab and low-dose cyclophosphamide yielded a 40% ORR and 90% DCR in platinum-sensitive high-grade endometrial cancer.

The folate receptor α ADC yielded responses, with a favorable safety profile, in patients with high-grade serous ovarian cancer in a phase 1 trial.

No grade 3 or greater treatment-related adverse effects or long-term safety signals emerged with gemogenovatucel-T in this ovarian cancer group.

The safety profile of atezolizumab plus bevacizumab and chemotherapy in this phase 3 trial was comparable with prior reports of the agents.

BI-1808 plus pembrolizumab was safe and well-tolerated among patients with recurrent ovarian cancer.

Among 35 patients with ovarian cancer treated with an antibody-based combination, the overall response rate was 23%, with a clinical benefit rate of 31%.